Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.
Malignant pleural mesothelioma (MPM) is an aggressive thoracic cancer with a high mortality rate as it responds poorly to standard therapeutic interventions. Our recent studies showed that expression of endothelial cell protein C receptor (EPCR) in MPM cells suppresses tumorigenicity. The present study was aimed to investigate the mechanism by which EPCR suppresses MPM tumor growth and evaluate whether EPCR gene therapy could suppress the progression of MPM in a mouse model of MPM. Measurement of cytokines from the pleural lavage showed that mice implanted with MPM cells expressing EPCR had elevated levels of IFNγ and TNFα compared to mice implanted with MPM cells lacking EPCR. In vitro studies demonstrated that EPCR expression renders MPM cells highly susceptible to IFNγ + TNFα-induced apoptosis. Intrapleural injection of Ad.EPCR into mice with an established MPM originating from MPM cells lacking EPCR reduced the progression of tumor growth. Ad.EPCR treatment elicited recruitment of macrophages and NK cells into the tumor microenvironment and increased IFNγ and TNFα levels in the pleural space. Ad.EPCR treatment resulted in a marked increase in tumor cell apoptosis. In summary, our data show that EPCR expression in MPM cells promotes tumor cell apoptosis, and intrapleural EPCR gene therapy suppresses MPM progression.
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, USA.
Shiva
S
Keshava
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, USA.
L Vijaya Mohan
LV
Rao
Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Texas, USA.
Usha R
UR
Pendurthi
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017209:Apoptosis; D045744:Cell Line, Tumor; D018450:Disease Progression; D000074283:Endothelial Protein C Receptor; D015316:Genetic Therapy; D005822:Genetic Vectors; D057809:HEK293 Cells; D006801:Humans; D007371:Interferon-gamma / Q000502:physiology; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008264:Macrophages / Q000276:immunology; D008654:Mesothelioma / Q000473:pathology / Q000628:therapy*; D000086002:Mesothelioma, Malignant; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D035422:Pleural Cavity / Q000276:immunology / Q000473:pathology; D010997:Pleural Neoplasms / Q000473:pathology / Q000628:therapy*; D014161:Transduction, Genetic; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000074283:Endothelial Protein C Receptor; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma